MAP2K7 and colorectal carcinoma: The BEACON CRC trial has laid the basis for substantial survival improvement for BRAFV600E mutant patients, and further studies are investigating the combination of BRAF, MEK, and EGFR inhibitors in this category of patients with particularly poor prognosis [92,93,94,95].